What is the projected market valuation of the Gastrointestinal Bleeding Treatment Market by 2035?

The projected market valuation for the Gastrointestinal Bleeding Treatment Market is expected to reach 10.11 USD Billion by 2035. Read More

What was the market valuation of the Gastrointestinal Bleeding Treatment Market in 2024?

The overall market valuation for the Gastrointestinal Bleeding Treatment Market was 6.329 USD Billion in 2024. Read More

What is the expected CAGR for the Gastrointestinal Bleeding Treatment Market from 2025 to 2035?

The expected CAGR for the Gastrointestinal Bleeding Treatment Market during the forecast period 2025 - 2035 is 4.35%. Read More

Which drug class is projected to have the highest valuation in the Gastrointestinal Bleeding Treatment Market?

Proton Pump Inhibitors are projected to have the highest valuation, increasing from 2.5 USD Billion to 4.0 USD Billion. Read More

What are the projected valuations for Somatostatin Analogues in the Gastrointestinal Bleeding Treatment Market?

Somatostatin Analogues are expected to grow from 1.0 USD Billion to 1.5 USD Billion during the forecast period. Read More

How does the market for intravenous treatments compare to oral treatments in 2035?

By 2035, the market for intravenous treatments is projected to reach 4.12 USD Billion, while oral treatments are expected to reach 3.02 USD Billion. Read More

What is the expected market size for lower gastrointestinal bleeding treatments by 2035?

The market size for lower gastrointestinal bleeding treatments is anticipated to grow from 2.529 USD Billion to 4.05 USD Billion by 2035. Read More

Which key players are leading the Gastrointestinal Bleeding Treatment Market?

Key players in the market include Johnson & Johnson, AbbVie Inc., and Merck & Co., Inc., among others. Read More

What is the projected growth for vasopressin agonists in the Gastrointestinal Bleeding Treatment Market?

Vasopressin Agonists are expected to grow from 0.5 USD Billion to 0.8 USD Billion during the forecast period. Read More

What is the anticipated market size for variceal bleeding treatments by 2035?

The anticipated market size for variceal bleeding treatments is projected to increase from 1.271 USD Billion to 2.01 USD Billion by 2035. Read More

Gastrointestinal Bleeding Treatment Market

ID: MRFR/HC/29351-HCR

100 Pages

Rahul Gotadki

Last Updated: May 15, 2026

Gastrointestinal Bleeding Treatment Market Research Report By Drug Class (Vasopressin Agonists, Somatostatin Analogues, Proton Pump Inhibitors, H2 Receptor Antagonists, Antiplatelet Agents, Antifibrinolytic Agents), By Route of Administration (Intravenous, Oral, Endoscopic), By Indication (Upper Gastrointestinal Bleeding, Lower Gastrointestinal Bleeding, Variceal Bleeding) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Drug Class (USD Billion) | |
  1. 4.1.1 Proton Pump Inhibitors | |
  2. 4.1.2 Somatostatin Analogues | |
  3. 4.1.3 H2 Receptor Antagonists | |
  4. 4.1.4 Vasopressin Agonists | |
  5. 4.1.5 Antiplatelet Agents | |
  6. 4.1.6 Antifibrinolytic Agents |
2. 4.2 Healthcare, BY Route of Administration (USD Billion) | |
  1. 4.2.1 Intravenous | |
  2. 4.2.2 Oral | |
  3. 4.2.3 Endoscopic |
3. 4.3 Healthcare, BY Indication (USD Billion) | |
  1. 4.3.1 Upper Gastrointestinal Bleeding | |
  2. 4.3.2 Lower Gastrointestinal Bleeding | |
  3. 4.3.3 Variceal Bleeding |
4. 4.4 Healthcare, BY Region (USD Billion) | |
  1. 4.4.1 North America | | |
    1. 4.4.1.1 US | | |
    2. 4.4.1.2 Canada | |
  2. 4.4.2 Europe | | |
    1. 4.4.2.1 Germany | | |
    2. 4.4.2.2 UK | | |
    3. 4.4.2.3 France | | |
    4. 4.4.2.4 Russia | | |
    5. 4.4.2.5 Italy | | |
    6. 4.4.2.6 Spain | | |
    7. 4.4.2.7 Rest of Europe | |
  3. 4.4.3 APAC | | |
    1. 4.4.3.1 China | | |
    2. 4.4.3.2 India | | |
    3. 4.4.3.3 Japan | | |
    4. 4.4.3.4 South Korea | | |
    5. 4.4.3.5 Malaysia | | |
    6. 4.4.3.6 Thailand | | |
    7. 4.4.3.7 Indonesia | | |
    8. 4.4.3.8 Rest of APAC | |
  4. 4.4.4 South America | | |
    1. 4.4.4.1 Brazil | | |
    2. 4.4.4.2 Mexico | | |
    3. 4.4.4.3 Argentina | | |
    4. 4.4.4.4 Rest of South America | |
  5. 4.4.5 MEA | | |
    1. 4.4.5.1 GCC Countries | | |
    2. 4.4.5.2 South Africa | | |
    3. 4.4.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Johnson & Johnson (US) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 AbbVie Inc. (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Boehringer Ingelheim (DE) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Takeda Pharmaceutical Company Limited (JP) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 Fresenius Kabi AG (DE) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Amgen Inc. (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Merck & Co., Inc. (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Gilead Sciences, Inc. (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY DRUG CLASS |
7. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
8. 6.5 US MARKET ANALYSIS BY INDICATION |
9. 6.6 CANADA MARKET ANALYSIS BY DRUG CLASS |
10. 6.7 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
11. 6.8 CANADA MARKET ANALYSIS BY INDICATION |
12. 6.9 EUROPE MARKET ANALYSIS |
13. 6.10 GERMANY MARKET ANALYSIS BY DRUG CLASS |
14. 6.11 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
15. 6.12 GERMANY MARKET ANALYSIS BY INDICATION |
16. 6.13 UK MARKET ANALYSIS BY DRUG CLASS |
17. 6.14 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
18. 6.15 UK MARKET ANALYSIS BY INDICATION |
19. 6.16 FRANCE MARKET ANALYSIS BY DRUG CLASS |
20. 6.17 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
21. 6.18 FRANCE MARKET ANALYSIS BY INDICATION |
22. 6.19 RUSSIA MARKET ANALYSIS BY DRUG CLASS |
23. 6.20 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
24. 6.21 RUSSIA MARKET ANALYSIS BY INDICATION |
25. 6.22 ITALY MARKET ANALYSIS BY DRUG CLASS |
26. 6.23 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
27. 6.24 ITALY MARKET ANALYSIS BY INDICATION |
28. 6.25 SPAIN MARKET ANALYSIS BY DRUG CLASS |
29. 6.26 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
30. 6.27 SPAIN MARKET ANALYSIS BY INDICATION |
31. 6.28 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS |
32. 6.29 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
33. 6.30 REST OF EUROPE MARKET ANALYSIS BY INDICATION |
34. 6.31 APAC MARKET ANALYSIS |
35. 6.32 CHINA MARKET ANALYSIS BY DRUG CLASS |
36. 6.33 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
37. 6.34 CHINA MARKET ANALYSIS BY INDICATION |
38. 6.35 INDIA MARKET ANALYSIS BY DRUG CLASS |
39. 6.36 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
40. 6.37 INDIA MARKET ANALYSIS BY INDICATION |
41. 6.38 JAPAN MARKET ANALYSIS BY DRUG CLASS |
42. 6.39 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
43. 6.40 JAPAN MARKET ANALYSIS BY INDICATION |
44. 6.41 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS |
45. 6.42 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
46. 6.43 SOUTH KOREA MARKET ANALYSIS BY INDICATION |
47. 6.44 MALAYSIA MARKET ANALYSIS BY DRUG CLASS |
48. 6.45 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
49. 6.46 MALAYSIA MARKET ANALYSIS BY INDICATION |
50. 6.47 THAILAND MARKET ANALYSIS BY DRUG CLASS |
51. 6.48 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
52. 6.49 THAILAND MARKET ANALYSIS BY INDICATION |
53. 6.50 INDONESIA MARKET ANALYSIS BY DRUG CLASS |
54. 6.51 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
55. 6.52 INDONESIA MARKET ANALYSIS BY INDICATION |
56. 6.53 REST OF APAC MARKET ANALYSIS BY DRUG CLASS |
57. 6.54 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
58. 6.55 REST OF APAC MARKET ANALYSIS BY INDICATION |
59. 6.56 SOUTH AMERICA MARKET ANALYSIS |
60. 6.57 BRAZIL MARKET ANALYSIS BY DRUG CLASS |
61. 6.58 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
62. 6.59 BRAZIL MARKET ANALYSIS BY INDICATION |
63. 6.60 MEXICO MARKET ANALYSIS BY DRUG CLASS |
64. 6.61 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
65. 6.62 MEXICO MARKET ANALYSIS BY INDICATION |
66. 6.63 ARGENTINA MARKET ANALYSIS BY DRUG CLASS |
67. 6.64 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
68. 6.65 ARGENTINA MARKET ANALYSIS BY INDICATION |
69. 6.66 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS |
70. 6.67 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
71. 6.68 REST OF SOUTH AMERICA MARKET ANALYSIS BY INDICATION |
72. 6.69 MEA MARKET ANALYSIS |
73. 6.70 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS |
74. 6.71 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
75. 6.72 GCC COUNTRIES MARKET ANALYSIS BY INDICATION |
76. 6.73 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS |
77. 6.74 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
78. 6.75 SOUTH AFRICA MARKET ANALYSIS BY INDICATION |
79. 6.76 REST OF MEA MARKET ANALYSIS BY DRUG CLASS |
80. 6.77 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
81. 6.78 REST OF MEA MARKET ANALYSIS BY INDICATION |
82. 6.79 KEY BUYING CRITERIA OF HEALTHCARE |
83. 6.80 RESEARCH PROCESS OF MRFR |
84. 6.81 DRO ANALYSIS OF HEALTHCARE |
85. 6.82 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
86. 6.83 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
87. 6.84 SUPPLY / VALUE CHAIN: HEALTHCARE |
88. 6.85 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE) |
89. 6.86 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion) |
90. 6.87 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
91. 6.88 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
92. 6.89 HEALTHCARE, BY INDICATION, 2024 (% SHARE) |
93. 6.90 HEALTHCARE, BY INDICATION, 2024 TO 2035 (USD Billion) |
94. 6.91 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
95. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
96. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY INDICATION, 2025-2035 (USD Billion) |
97. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY INDICATION, 2025-2035 (USD Billion) |
98. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY INDICATION, 2025-2035 (USD Billion) |
99. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY INDICATION, 2025-2035 (USD Billion) |
100. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY INDICATION, 2025-2035 (USD Billion) |
101. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY INDICATION, 2025-2035 (USD Billion) |
102. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY INDICATION, 2025-2035 (USD Billion) |
103. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY INDICATION, 2025-2035 (USD Billion) |
104. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY INDICATION, 2025-2035 (USD Billion) |
105. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY INDICATION, 2025-2035 (USD Billion) |
106. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY INDICATION, 2025-2035 (USD Billion) |
107. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY INDICATION, 2025-2035 (USD Billion) |
108. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY INDICATION, 2025-2035 (USD Billion) |
109. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY INDICATION, 2025-2035 (USD Billion) |
110. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY INDICATION, 2025-2035 (USD Billion) |
111. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY INDICATION, 2025-2035 (USD Billion) |
112. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY INDICATION, 2025-2035 (USD Billion) |
113. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY INDICATION, 2025-2035 (USD Billion) |
114. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY INDICATION, 2025-2035 (USD Billion) |
115. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY INDICATION, 2025-2035 (USD Billion) |
116. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY INDICATION, 2025-2035 (USD Billion) |
117. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY INDICATION, 2025-2035 (USD Billion) |
118. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY INDICATION, 2025-2035 (USD Billion) |
119. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY INDICATION, 2025-2035 (USD Billion) |
120. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY INDICATION, 2025-2035 (USD Billion) |
121. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY INDICATION, 2025-2035 (USD Billion) |
122. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY INDICATION, 2025-2035 (USD Billion) |
123. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY INDICATION, 2025-2035 (USD Billion) |
124. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY INDICATION, 2025-2035 (USD Billion) |
125. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
126. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Gastrointestinal Bleeding Treatment Market Segmentation

Gastrointestinal Bleeding Treatment Market By Drug Class (USD Billion, 2025-2035)

Proton Pump Inhibitors
Somatostatin Analogues
H2 Receptor Antagonists
Vasopressin Agonists
Antiplatelet Agents
Antifibrinolytic Agents

Gastrointestinal Bleeding Treatment Market By Route of Administration (USD Billion, 2025-2035)

Intravenous
Oral
Endoscopic

Gastrointestinal Bleeding Treatment Market By Indication (USD Billion, 2025-2035)

Upper Gastrointestinal Bleeding
Lower Gastrointestinal Bleeding
Variceal Bleeding

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035